COVID-19; Interchange of vaccine products; Revaccination with different COVID-19 vaccine; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID-19), INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) and COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.    Co-suspect products included non-company products TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for an unknown indication and COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (JANSSEN COVID-19 VACCINE) for an unknown indication.    No Medical History information was reported.   On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form, dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) 1 dosage form and dose of COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (JANSSEN COVID-19 VACCINE) (unknown route) 1 dosage form. On an unknown date, the patient experienced COVID-19 (COVID-19), INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) and COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine). At the time of the report, COVID-19 (COVID-19), INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) and COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported.   No treatment information was provided.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.  Company comment-This spontaneous case concerns a patient of unspecified age and gender with no medical history reported, who experienced the unexpected non serious AESI event of COVID-19 on unknown date in the context of mRNA-1273 vaccination.  Latency cannot be assessed since vaccination date nor event onset date were provided. Patient had received a dose of each vaccine on unknown dates with TOZINAMERAN and JANSSEN COVID-19 VACCINE, Interchange of vaccine products was noted. No further information on detailed clinical course, investigations, treatment of the events was available in the report. Outcome of the event was unknown at the time of report. Current pandemic situation of COVID 19 may remain as confounders to the event Covid -19. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report. Event seriousness assessed as per medical judgement   Most recent FOLLOW-UP information incorporated above includes: On 05-Nov-2021: Non-significant follow up received included no new information.; Sender's Comments: This spontaneous case concerns a patient of unspecified age and gender with no medical history reported, who experienced the unexpected non serious AESI event of COVID-19 on unknown date in the context of mRNA-1273 vaccination.  Latency cannot be assessed since vaccination date nor event onset date were provided. Patient had received a dose of each vaccine on unknown dates with TOZINAMERAN and JANSSEN COVID-19 VACCINE, Interchange of vaccine products was noted. No further information on detailed clinical course, investigations, treatment of the events was available in the report. Outcome of the event was unknown at the time of report. Current pandemic situation of COVID 19 may remain as confounders to the event Covid -19. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report. Event seriousness assessed as per medical judgement